Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

Clinical Immunology

Volumn 134, Issue 2, 2010, Pages 140-147

  Routy, Jean Pierre ^a,b   Boulassel, Mohamed Rachid ^a   Yassine Diab, Bader ^b,c,d   Nicolette, Charles ^e   Healey, Don ^e   Jain, Renu ^e   Landry, Claire ^c,d   Yegorov, Oleg ^b,c,d   Tcherepanova, Irina ^e   Monesmith, Tamara ^e   Finke, Lothar ^e   Sékaly, Rafick Pierre ^b,c,d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Centre Hospitalier   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d National Immune Monitoring Laboratory   (Canada)

^e Argos Therapeutics Inc   (United States)

Author keywords

Acquired immunodeficiency syndrome; Dendritic cells; HIV; Immunotherapy; Vaccine

Indexed keywords

AGS 004; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD40 LIGAND; GAG PROTEIN; NEF PROTEIN; PROTEINASE INHIBITOR; REV PROTEIN; RHEUMATOID FACTOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; VPR PROTEIN; ANTIRETROVIRUS AGENT;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNITY; AUTOTRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DENDRITIC CELL; DIARRHEA; DRUG MANUFACTURE; DRUG SAFETY; ELECTROPORATION; EYE INFECTION; FATIGUE; FEASIBILITY STUDY; FLU LIKE SYNDROME; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL PAIN; HEADACHE; HEMATOCHEZIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INSOMNIA; LABORATORY TEST; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MONOCYTE; NAUSEA; PAIN; PILOT STUDY; PLASMA; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; VIRUS LOAD; VITAL SIGN; CD4+ T LYMPHOCYTE; CELL COUNT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; TRANSPLANTATION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; DENDRITIC CELLS; ELECTROPORATION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PILOT PROJECTS; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 73549125003     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.09.009     Document Type: Article

References (39)

1. Kinloch-de Loes S. Role of therapeutic vaccines in the control of HIV-1. J. Antimicrob. Chemother. 53 (2004) 562-566
2. Schmitz J.E. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
3. Addo M.M., Draenert R., Rathod A., et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2 (2007) e321
4. Goulder P.J. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412 (2001) 334-338
5. Barouch D.H., Kunstman J., Kuroda M.J., et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415 (2002) 335-339
6. Vaccari M., Mattapallil J., Song K., et al. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J. Virol. 82 (2008) 9629-9638
7. McNeil A.C., Shupert W.L., Iyasere C.A., et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13878-13883
8. Younes S.A., Yassine-Diab B., Dumont A.R., et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198 (2003) 1909-1922
9. Lichterfeld M., Yu X., Mui S., et al. Selective depletion of high-avidity human immunodeficiency virus type 1(HIV-1)-specific CD8+ T cells after early HIV-1 infection. J. Virol. 81 (2007) 199-214
10. Zanussi S., Simonelli C., D'Andrea M., et al. CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin. Exp. Immunol. 105 (1996) 220-224
11. Trautmann L., Janbazian L., Chomont N., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12 (2006) 1198-1202
12. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 (2007) 419-426
13. Nicolette C.A., Healey D., Tcherepanova I., et al. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 25 Suppl. 2 (2007) B47-B60
14. Osada T., Clay T.M., Woo C.Y., Morse M.A., and Lyerly H.K. Dendritic cell-based immunotherapy. Int. Rev. Immunol. 25 (2006) 377-413
15. Connolly N.C., Whiteside T.L., Wilson C., et al. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin. Vaccine Immunol. 15 (2008) 284-292
16. Garcia F., Lejeune M., Climent N., et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 191 (2005) 1680-1685
17. Lu W., Arraes L.C., Ferreira W.T., and Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10 (2004) 1359-1365
18. Whiteside T.L., Piazza P., Reiter A., et al. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin. Vaccine Immunol. 16 (2009) 233-240
19. Ide F., Nakamura T., Tomizawa M., et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J. Med. Virol. 78 (2006) 711-718
20. DeBenedette M.A., Calderhead D.M., Ketteringham H., et al. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J. Immunol. 181 (2008) 5296-5305
21. Calderhead D.M., DeBenedette M.A., Ketteringham H., et al. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J. Immunol. 31 (2008) 731-741
22. Tcherepanova I., Harris J., Starr A., et al. Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection. PLoS ONE 3 (2008) e1489
23. Addo M.M., Yu X.G., Rosenberg E.S., Walker B.D., and Altfeld M. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol. 21 (2002) 671-678
24. Van Gulck E.R., Ponsaerts P., Heyndrickx L., et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 107 (2006) 1818-1827
25. Altfeld M., Addo M.M., Eldridge R.L., et al. Vpr is preferentially targeted by CTL during HIV-1 infection. J. Immunol. 167 (2001) 2743-2752
26. Novitsky V., Cao H., Rybak N., et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J. Virol. 76 (2002) 10155-10168
27. Quaranta M.G., Mattioli B., Giordani L., and Viora M. The immunoregulatory effects of HIV-1 Nef on dendritic cells and the pathogenesis of AIDS. FASEB J. 20 (2006) 2198-2208
28. Majumder B., Janket M.L., Schafer E.A., et al. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape. J. Virol. 79 (2005) 7990-8003
29. Tcherepanova I., Starr A., Lackford B., et al. The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90. PLoS One 4 (2009) e5853
30. Tcherepanova I.Y., Adams M.D., Feng X., et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol. Biol. 9 (2008) 90
31. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 21 (2003) 873-886
32. Gilboa E., and Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199 (2004) 251-263
33. Hao S., Ye Z., and Yang J. Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity. Cancer Biother. Radiopharm. 21 (2006) 146-154
34. Morse M., Coleman R., and Akabani G. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59 (1999) 56-58
35. Van Kaer L. Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens 60 (2002) 1-9
36. Autran B., Murphy R.L., Costagliola D., et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 22 (2008) 1313-1322
37. Appray V., Douek D., Price D., and CD8+ T. cell efficacy in vaccination and disease. Nat. Med. 14 (2008) 623-628
38. Jacobson J.M., Turner B.J., and Abrutyn E. Trials that matter: CD4+ T-lymphocyte count-guided interruption of antiretroviral therapy in HIV-infected patients. Ann. Intern. Med. 146 (2007) 682-683
39. Kutzler M., and Jacobson J.M. Treatment interruption as a tool to measure changes in immunologic response to HIV-1. Curr. Opin. HIV AIDS 3 (2008) 131-135